Leveraging in vitro and pharmacokinetic models to support bench to bedside investigation of XTMAB-16 as a novel pulmonary sarcoidosis treatment

Overview of attention for article published in Frontiers in Pharmacology, March 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter: 6 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 66,599 followers.

RT @cpa61: Leveraging in vitro and pharmacokinetic models to support bench to bedside investigation of XTMAB-16 as a novel pulmonary sarcoi…

27 Nov 2023

Reply Repost Favourite

Leveraging in vitro and pharmacokinetic models to support bench to bedside investigation of XTMAB-16 as a novel pulmonary sarcoidosis treatment https://t.co/eJCGqiVtkg https://t.co/TGWYUHeOfA

09 Nov 2023

Reply Repost Favourite

Leveraging in vitro and pharmacokinetic models to support bench to bedside investigation of XTMAB-16 as a novel pulmonary sarcoidosis treatment https://t.co/Mrsrs0wgv5 https://t.co/KZKbKlQjvI

08 Nov 2023

Reply Repost Favourite

Leveraging in vitro and pharmacokinetic models to support bench to bedside investigation of XTMAB-16 as a novel pulmonary sarcoidosis treatment https://t.co/SpbAP630sW https://t.co/wbS7XfMJjs

05 Nov 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.